INTRODUCTION

In 2012, the US Preventive Services Task Force (USPSTF) issued a recommendation against prostate-specific antigen (PSA) screening. These recommendations were based on 2 large randomized studies studying the impact of PSA screening [1,2]. The U.S. Prostate, Lung, Colorectal, and Ovarian Cancer screening trial (PLCO) randomly assigned...
Nevertheless, once the USPSTF guidelines were issued, decreased prostate biopsies. McGinley et al. [14] reported that dramatic changes in primary care and urologic practices led to decreased PSA screening and biopsies [7-10]. After 2012, national declines in PSA and digital rectal exam (DRE) screenings were reported. Significant decreased PSA testing by primary care physicians was reported for all men following the USPSTF recommendations [11]. An analysis of the National health Interview Survey demonstrated that while screening decreased in all age groups, the largest drop occurred in men 50–59 years of age in whom absolute and relative screening rates declined by 8% and 25% [12]. The National Ambulatory Medical Care survey performed annually at the Centers for Disease Control and Prevention demonstrated a relative 64% decrease in DRE and a 39% decrease in PSA testing after the USPSTF recommendations were published [13].

By design, decreased prostate cancer screening leads to decreased prostate biopsies. McGinley et al. [14] reported that their large urology group practice completed 16.4% fewer evaluations for elevated PSA levels and 21.4% fewer prostate biopsies in the 2 years following the recommendations. Bhindi et al. [15] reported a significant decrease in the overall number of biopsies and noted that the number of monthly biopsies decreased from 58 to 35 in the 12 months following the USPSTF guidelines. More worrisome was a decrease in the absolute number of intermediate to high Gleason grade tumors suggesting that a number of clinically relevant cancers are going undiagnosed. Similarly, Banerji et al. [16] reported a 31% decrease in the absolute number of biopsies and a 33% higher relative risk of being diagnosed with high-risk prostate cancer. In the 2 and a half years after the USPSTF recommendations, patients were more likely to be diagnosed with high-risk as opposed to intermediate risk disease. These 2 studies were the first to show a significant impact of reduced screening on Gleason score at diagnosis.

In order to evaluate the effect of the USPSTF recommendations on prostate cancer diagnoses in a large suburban private practice setting and whether decreased screening leads to a higher incidence of high grade disease, we compared biopsy results from 2011 before the USPSTF recommendation and 2014 after the guidelines were widely adopted.

**MATERIALS AND METHODS**

We utilized data from a large urology group practice composed of 30 urologists at 2 free standing urology centers. No significant change in urology or pathology staffing or the referring practices occurred during the study period. We retrospectively collected data from all patients who underwent transrectal ultrasound guided prostate needle biopsy (PNB) in 2011 and 2014. The study was reviewed by our internal research committee. It was determined that this research project would qualify as exempt from an IRB review since the project involved research pertaining to the collection and analysis of existing data, documents, records, pathologic reports, and diagnostic specimens in such a manner that subjects could not be identified, directly or through identifiers linked to the subjects. As such, there was no potential harm to individual patients. All biopsies were submitted to a central pathology lab and reviewed by a dedicated uropathologist. Patient demographics, PSA, percent positive biopsies and Gleason scores were collected and compared between patient cohorts undergoing PNB in 2011 and those in 2014.

Data was summarized using descriptive statistics including frequency and percentage for categorical data and means and standard deviation for continuous data. Patient characteristics were compared between the 2 cohorts using a t-test for continuous variables (mean age) and a Pearson
chi-square test for categorical variables (categorized age, PSA, and Gleason score). PSA values were not normally distributed and hence were analyzed as categorical data. Statistical significance testing was performed using a test p-value of 0.05 or less as a cutoff for significance. All analyses were performed using SAS 9.4 (SAS Institute Inc, Cary, NC, USA). Statistical testing was 2 sided with a threshold of statistical significance at p<0.05.

RESULTS

A total of 4,178 biopsies were identified – 2,513 in 2011 and 1,665 in 2014. The baseline patient characteristics for the 2 years are shown in Table 1. The percentage of positive biopsies was 27% in 2011 versus 34% in 2014 (p<0.0001). After the USPSTF recommendations, 34% fewer biopsies were performed with a 29% increase in positive biopsy rates. For the 2011 cohort, the median age was 68 years (range, 44–95 years), the median PSA was 5.3 ng/mL (range, 0.2–978 ng/mL) and the median Gleason score was 6 (range, 6–10). The 2014 cohort had a median age of 67 years (range, 40–92 years), a median PSA of 5.8 ng/mL (range, 0.05–1,016 ng/mL) and a median Gleason score of 7 (range, 6–10). The PSA values did not differ between the 2 years analyzed (chi-square; p=0.352).

Among patients with positive biopsies, we found statistically significant differences between the 2 cohorts in the median ages and Gleason scores. Patients were about 1 year younger in 2014 compared to 2011 (t-test; p=0.043). The percentage of patients with positive biopsies having high grade disease doubled in 2014. High Gleason scores (8–10) were diagnosed in 18.5% of the 2014 positive biopsies versus 9% in the 2011 positive biopsies (chi-square; p<0.0001). Age, PSA, and Gleason score differences of the patients in the two cohorts are depicted in Table 2.

DISCUSSION

After the introduction of widespread PSA screening in the US, the lifetime risk of prostate cancer rose from 9% in 1985 to 16% in 2009 with nearly 90% detected through screening. These screening detected cancers are more likely to be localized and less likely to be poorly differentiated [17]. During this same period, the lifetime risk of dying from prostate cancer fell from 3% to 2.4%. This decline in mortality is attributed to earlier detection and treatment as well as improvement in the various treatment modalities [18]. The 2012 USPSTF guidelines have dramatically changed prostate cancer management in the US through declines in PSA screening, prostate biopsies, and prostate cancer

Table 1. Patient characteristics for the calendar years 2011 and 2014 groups

| Characteristic       | 2011 (n=669) | 2014 (n=572) | p-value |
|----------------------|-------------|-------------|---------|
| **Age categories (y)** |             |             |         |
| ≤50                  | 19 (2.84)   | 24 (4.20)   | 0.385   |
| 51–60                | 125 (18.68) | 119 (20.80) |         |
| 61–70                | 269 (40.21) | 235 (41.08) |         |
| 71–80                | 202 (30.19) | 156 (27.27) |         |
| >80                  | 54 (8.07)   | 38 (6.64)   |         |
| **Age (y)**          | 67.70±8.95  | 66.67±8.99  | 0.043   |
| **PSA categories (ng/mL)** |           |             | 0.352   |
| Missing              | 135 (20.18) | 5 (0.87)    |         |
| <4                   | 116 (17.34) | 113 (19.76) |         |
| 4, <10               | 328 (49.03) | 338 (59.09) |         |
| 10, <20              | 56 (8.37)   | 65 (11.36)  |         |
| ≥20                  | 34 (5.08)   | 51 (8.92)   |         |
| **GS categories**    |             |             | <0.0001 |
| Missing              | 2 (0.30)    | 8 (1.40)    |         |
| 6                    | 336 (50.22) | 244 (42.66) |         |
| 7 (3+4)              | 190 (28.40) | 129 (22.55) |         |
| 7 (4+3)              | 79 (11.81)  | 85 (14.86)  |         |
| 8–10                 | 62 (9.27)   | 106 (18.53) |         |

Values are presented as number (%) or mean±standard deviation.
PSA, prostate specific antigen; GS, Gleason score.
diagnoses [12,13]. In recommending against PSA screening, the USPSTF described false positive tests, overdiagnosis, and overtreatment of indolent disease as a major source of unnecessary harm from screening. However newer biomarkers and imaging techniques are refining the screening process and are helpful in identifying patients at greater risk of having intermediate and high-risk disease. Prostate Health Index multibiomarker test, PCA3 and TMPRSS2:ERG, and the 4K score panel are validated biomarkers that can be added to the prebiopsy algorithm to help determine which of the patients with an elevated screening PSA are most likely to benefit from a biopsy [19]. Multiparametric magnetic resonance imaging (Mp-MRI) has a high negative predictive value of 80%–90% and it is has been suggested that patients with elevated screening PSA who have PIRADS 1 and 2 lesions do not require biopsy. Conversely, those with PIRADS 4 and 5 lesions are likely to have significant cancers and biopsy is warranted. Due to interobserver variability, there is less consistency regarding PIRAD 3 lesions however Liddel et al. [20] reported that only 6.5% of these patients are found to have cancer and noted that lesions in the transition zone were more likely to represent a benign process. Thus, the use of emerging biomarkers along with prebiopsy Mp-MRI is an evolving improvement over PSA alone in distinguishing between indolent and clinically significant prostate cancers and may help clarify which patients require prostate biopsy.

A significant portion of the PSA screening controversy is related to the economic impact of prostate cancer on the US health care system. Although the PSA test is not expensive, the downstream effects of an elevated PSA including biopsy and management of postbiopsy complications are significant. In a Surveillance, Epidemiology, and End Results-Medicare analysis of PSA screening and subsequent related procedures from 2007 through 2009, Ma et al. [21] reported an annual expenditure of US $450 million. Prostate biopsies and management of postprocedure complications accounted for 72% of the total cost. The economic burden of screening must be weighed against the potential cost savings of earlier diagnoses as studies have shown a direct correlation between treatment cost per patient and the risk group at time of diagnosis [22,23]. One way to assess the cost effectiveness of PSA screening is to assess the value added by various screening strategies. Roth et al. [24] created a microsimulation model and tested 18 PSA screening strategies. The screening costs, deaths prevented, additional life years, and quality of life years (QALY) were compared to a no screening approach. All strategies achieved added life years and increased expenditure with the costs ranging from US $7,335 to US $21,649 per life year. With selective treatment including conservative management of low risk patients, all strategies were associated with increased QALY.

| Table 2. Age, PSA values, and GS categories by the calendar years 2011 and 2014 |
|-----------------|-----------------|
| Characteristic | 2011 (n=669) | 2014 (n=572) |
| Age categories (y) | | |
| ≤50 | 19 (2.84) | 24 (4.2) |
| 51–60 | 125 (18.68) | 119 (20.8) |
| 61–70 | 269 (40.21) | 235 (41.08) |
| 71–80 | 202 (30.19) | 156 (27.27) |
| >80 | 54 (8.07) | 38 (6.64) |
| PSA categories (ng/mL) | | |
| Missing | 135 (20.18) | 5 (0.87) |
| <4 | 116 (17.34) | 113 (19.76) |
| 4, <10 | 328 (49.03) | 338 (59.09) |
| 10, <20 | 56 (8.37) | 65 (11.36) |
| ≥20 | 34 (5.08) | 51 (8.92) |
| GS categories | | |
| Missing | 2 (0.3) | 8 (1.4) |
| 6 | 336 (50.22) | 244 (42.66) |
| 7 (3+4) | 190 (28.4) | 129 (22.55) |
| 7 (4+3) | 79 (11.81) | 85 (14.86) |
| 8–10 | 62 (9.27) | 106 (18.53) |

Values are presented as number (%). PSA, prostate specific antigen; GS, Gleason score.
and several were cost effective in terms of cost per QALY. Additional information regarding new screening tests, ideal screening population, proper testing intervals, and appropriate treatment interventions will help define the most cost effective screening protocol.

While decreased screening can reduce the diagnosis of indolent cancers and avoid unnecessary treatment, it also may lead to missed opportunities to diagnose prostate cancers when they are lower in grade and stage and may be more curable. Widespread PSA screening has changed the clinical characteristics of patients at the time of diagnosis. In an analysis from the Cleveland Clinic, patients diagnosed between 1986 and 1992 (pre-PSA) had more aggressive cancers evidenced by higher Gleason scores and T stage compared with those diagnosed from 1993 to 1996 (post-PSA). Additionally, PSA screening has resulted in a decreased burden of metastatic prostate cancer. Even when controlling for variables known to impact outcome, a significant difference in rates of metastases has been reported – with 18% of screened patients developing metastases compared with 26% in the pre PSA era [25]. If the pre-PSA era rates of metastatic disease at diagnosis were present in the modern US population – the total number of men presenting with metastases would be triple the current rate observed [26]. The inherent danger in abandoning PSA testing is that the reduction in unnecessary biopsies may be at the cost of detecting clinically relevant cancers when they are most treatable. Given the relatively indolent nature of many prostate cancers, the impact of reduced screening and biopsies on prostate cancer specific mortality will take more than 10 years to become evident [3]. A more readily available surrogate measure is a change in the Gleason score distribution.

**CONCLUSIONS**

After widespread implementation of the USPSTF guidelines, our center performed 34% fewer biopsies and found a significantly higher incidence of high grade disease. The percentage of patients with positive biopsies having Gleason score 8–10 doubled within 2 years of the recommendations against screening. During this period, no significant change in urology or pathology staffing or the referring practices occurred. The only change was that the primary care physicians increasingly accepted a no screening policy. Our findings are similar to those of Banerji et al. [16] who reported a 31% decrease in biopsies and a 33% higher relative risk of being diagnosed with high-risk prostate cancer. These results provide evidence to the growing concern that if PSA testing continues to be abandoned, we will lose the ability to identify patients with low to intermediate grade disease and encounter higher mortality rates.

**CONFLICTS OF INTEREST**

The authors have nothing to disclose.

**REFERENCES**

1. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104:125-32.

2. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.

3. Penson DF. The pendulum of prostate cancer screening. JAMA 2015;314:2031-3.

4. Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:120-34.

5. Carlsson S, Vickers AJ, Roobol M, Eastham J, Scardino P, Lilja H, et al. Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol 2012;30:2581-4.

6. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Göteborg randomized population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725-32.

7. Wallner LP, Hsu JW, Loo RK, Palmer-Toy DE, Schottinger JE, Jacobsen SJ. Trends in prostate-specific antigen screening, prostate biopsies, urology visits, and prostate cancer treatments from 2000 to 2012. Urology 2015;86:498-505.

8. Gershman B, Van Houten HK, Herrin J, Moreira DM, Kim SP, Shah ND, et al. Impact of prostate-specific antigen (PSA) screening trials and revised PSA screening guidelines on rates of prostate biopsy and postbiopsy complications. Eur Urol 2017;71:55-65.

9. Barocas DA, Mallin K, Graves AJ, Penson DF, Palis B, Winchester DP, et al. Effect of the USPSTF grade D recommendation against screening for prostate cancer on incident prostate cancer diagnoses in the United States. J Urol 2015;194:1587-93.

10. Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA 2015;314:2054-61.
11. Cohn JA, Wang CE, Lakeman JC, Silverstein JC, Brendler CB, Novakovic KR, et al. Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation. Urol Oncol 2014;32:41.e23-30.
12. Drazer MW, Huo D, Eggener SE. National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol 2015;33:2416-23.
13. Shoag J, Halpern JA, Lee DJ, Mittal S, Ballman KV, Barbieri CE, et al. Decline in prostate cancer screening by primary care physicians: an analysis of trends in the use of digital rectal examination and prostate specific antigen testing. J Urol 2016;196:1047-52.
14. McGinley KF, McMahon GC, Brown GA. Impact of the US Preventive Services Task Force grade D recommendation: assessment of evaluations for elevated prostate-specific antigen and prostate biopsies in a large urology group practice following statement revision. Rev Urol 2015;17:171-7.
15. Bhindi B, Mamdani M, Kulkarni GS, Finelli A, Hamilton RJ, Trachtenberg J, et al. Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates. J Urol 2015;193:1519-24.
16. Banerji JS, Wolff EM, Massman JD 3rd, Odem-Davis K, Porter CR, Cormann JM. Prostate needle biopsy outcomes in the era of the U.S. Preventive Services Task Force recommendation against prostate specific antigen based screening. J Urol 2016;195:66-73.
17. Hoffman RM, Stone SN, Espey D, Potosky AL. Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA. BMC Cancer 2005;5:27.
18. Albertssten P. Screening for prostate cancer. 9th ed. Philadelphia: Lippincott, Williams and Wilkins; 2011. Chapter 61.
19. Punnen S, Pavan N, Parekh DJ. Finding the wolf in sheep's clothing: The 4K score is a novel blood test that can accurately identify the risk of aggressive prostate cancer. Rev Urol 2015;17:3-13.
20. Liddell H, Jyoti R, Haxhimolla HZ. mp-MRI prostate characterised PIRADS 3 lesions are associated with a low risk of clinically significant prostate cancer - a retrospective review of 92 biopsied PIRADS 3 lesions. Curr Urol 2015;8:96-100.
21. Ma X, Wang R, Long JB, Ross JS, Soulos PR, Yu JB, et al. The cost implications of prostate cancer screening in the Medicare population. Cancer 2014;120:96-102.
22. Stokes ME, Black L, Benedict A, Roehrborn CG, Albertsen P. Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data. Prostate Cancer Prostatic Dis 2010;13:278-84.
23. Sanyal C, Aprikian AG, Cury FL, Chevalier S, Dragomir A. Management of localized and advanced prostate cancer in Canada: a lifetime cost and quality-adjusted life-year analysis. Cancer 2016;122:1085-96.
24. Roth JA, Gulati R, Gore JL, Cooperberg MR, Etzioni R. Economic analysis of prostate-specific antigen screening and selective treatment strategies. JAMA Oncol 2016;2:890-8.
25. Ciezki JP, Reddy CA, Kupelian PA, Klein EA. Effect of prostate-specific antigen screening on metastatic disease burden 10 years after diagnosis. Urology 2012;80:367-72.
26. Scosyrev E, Wu G, Mohile S, Messing EM. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. Cancer 2012;118:5768-76.